Abstract
Glycogen synthase kinase 3 (GSK-3) inhibitors have aroused a great interest for medicinal chemists and pharmaceutical companies in the last years. In fact, some candidates have reached to clinical trials as disease modifying drugs for Alzheimer’s disease. This review will cover the great improvements recently done in the field of GSK-3 inhibitors switching from random discovery to rational drug design, from full GSK-3 inhibition to mild and controlled activity of enzyme reduction, from unknown therapeutic potential to validated efficacy in different animal models of diseases. Moreover some lessons learnt from clinical trials will be described with the aim to improve future designs. Collective results highlight the importance of mild GSK-3 inhibitors as innovative drugs for severe human unmet diseases.
Keywords: GSK-3 inhibitors, neurodegenerative diseases, Alzheimer’s disease, clinical trials, drug design.
Current Topics in Medicinal Chemistry
Title:Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease
Volume: 13 Issue: 15
Author(s): Ana Martinez, Daniel I. Perez and Carmen Gil
Affiliation:
Keywords: GSK-3 inhibitors, neurodegenerative diseases, Alzheimer’s disease, clinical trials, drug design.
Abstract: Glycogen synthase kinase 3 (GSK-3) inhibitors have aroused a great interest for medicinal chemists and pharmaceutical companies in the last years. In fact, some candidates have reached to clinical trials as disease modifying drugs for Alzheimer’s disease. This review will cover the great improvements recently done in the field of GSK-3 inhibitors switching from random discovery to rational drug design, from full GSK-3 inhibition to mild and controlled activity of enzyme reduction, from unknown therapeutic potential to validated efficacy in different animal models of diseases. Moreover some lessons learnt from clinical trials will be described with the aim to improve future designs. Collective results highlight the importance of mild GSK-3 inhibitors as innovative drugs for severe human unmet diseases.
Export Options
About this article
Cite this article as:
Martinez Ana, Perez I. Daniel and Gil Carmen, Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease, Current Topics in Medicinal Chemistry 2013; 13 (15) . https://dx.doi.org/10.2174/15680266113139990138
DOI https://dx.doi.org/10.2174/15680266113139990138 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets Plasma Clusterin Levels and the rs11136000 Genotype in Individuals with Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Placental Cytokines in the Pathogenesis of Preeclampsia and Hellp Syndrome
Current Women`s Health Reviews The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Bioinformatics Studies on Induced Pluripotent Stem Cell
Current Bioinformatics Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Letters in Drug Design & Discovery A Comprehensive Review on Recent Developments in the Field of Biological Applications of Potent Pyrazolines Derived from Chalcone Precursors
Letters in Drug Design & Discovery Drugs from the Sea: Conopeptides as Potential Therapeutics
Current Medicinal Chemistry Computer Simulations of the Retinoid X Receptor: Conformational Dynamics and Allosteric Networks
Current Topics in Medicinal Chemistry Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Preparation and Characterization of Binary and Ternary Complexes of Dihydroartremisinin with Hydroxypropyl-β-cyclodextrin, Palmitic acid and Polyvinylpyrrolidone K30
Current Pharmaceutical Analysis A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency
Endocrine, Metabolic & Immune Disorders - Drug Targets The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy Nucleobase Modifications in Peptide Nucleic Acids
Current Topics in Medicinal Chemistry Reversal of Informational Entropy and the Acquisition of Germ-like Immortality by Somatic Cells
Current Aging Science Alcoholism and its Effects on the Central Nervous System
Current Neurovascular Research Improved Hepatic Differentiation Strategies for Human Induced Pluripotent Stem Cells
Current Molecular Medicine Zinc Chloride Catalyzed Collective Synthesis of Arylmethylene Bis(3- hydroxy-2-cyclohexene-1-ones) and 1,8-Dioxo-octahydroxanthene/acridine Derivatives
Letters in Organic Chemistry T Cell Homeostasis in Centenarians: From the Thymus to the Periphery
Current Pharmaceutical Design